Scinai Immunotherapeutics Gains Clearance from Italy for Pincell Acquisition Scinai Immunotherapeutics has received regulatory clearance in Italy for the acquisition of Pincell S.r.l., marking a significant step in its growth strategy in biotechnology.

Scinai Immunotherapeutics Gains Clearance from Italy for Pincell Acquisition #Italy #Jerusalem #Immunotherapy #Scinai #Pincell

Pioneering Treatment for Rare Skin Conditions: Scinai Webinar Highlights New Drug Development Scinai Immunotherapeutics is set to explore a groundbreaking drug for rare skin diseases in an upcoming webinar, focusing on PC111's significance.

Pioneering Treatment for Rare Skin Conditions: Scinai Webinar Highlights New Drug Development #Scinai_Immunotherapeutics #Israel #Jerusalem #Pincell #PC111

Scinai to Acquire Pincell and Advance Development of Groundbreaking Monoclonal Antibody Scinai confirms its acquisition of Pincell, focusing on a novel antibody for treating severe dermatological conditions and advancing its development with a significant grant application.

Scinai to Acquire Pincell and Advance Development of Groundbreaking Monoclonal Antibody #Israel #Jerusalem #Scinai #Pincell #PC111